Scrip
US FDA clears Lupin's Mandideep facility
21 January 2010
Anju Ghangurde
The US
FDA has cleared
Lupin's Mandideep facility in India, after the company addressed all concerns related to the warning letter issued by the agency last May.
The company said that it had received official communication from the FDA on the satisfactory resolution of the warning letter. "In...
Please Login to read the full article.
21 January 2010
Anju Ghangurde
The company said that it had received official communication from the FDA on the satisfactory resolution of the warning letter. "In...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Genzyme troubled by new contamination problems at manufacturing plant
- US FDA blocks drug imports from two Canadian Apotex facilities
- Regenerative Sciences fights FDA charge that its stem cell-based procedure should be classed as a "drug"
- Sanofi Pasteur and Cangene get FDA "untitled" letters for GMP deviations
COMMENT
Other Informa Comment
FEATURES
- Recipharm sees opportunity to ride wave of CDMO consolidation
- Face-to-Face: Trophos - The French firm that hooked Actelion
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
